Portal de investigação
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Claggett, BL
- Liu, JK
- Sharma, A
- Desai, AS
- Anand, IS
- O'Meara, E
- Rouleau, JL
- De Denus, S
- Pitt, B
- Pfeffer, MA
- Zannad, F
- Solomon, SD
Unidades de investigação
Abstract
Background: Inflammation plays a central role in the genesis and progression of heart failure with preserved ejection fraction (HFpEF). C -reactive protein (CRP) is widely used as means to assess systemic inflammation, and elevated levels of CRP have been associated with poor HF prognosis. Identification of chronic low-grade inflammation in outpatients can be performed measuring high -sensitivity CRP (hsCRP). The clinical characteristics and outcome associations of a pro -inflammatory state among outpatients with HFpEF requires further study. Aims: Using a biomarker subset of TOPCAT-Americas (NCT00094302), we aim to characterize HFpEF patients according to hsCRP levels and study the prognostic associations of hsCRP. Methods: hsCRP was available in a subset of 232 participants. Comparisons were performed between patients with hsCRP <2 mg/L and >= 2 mg/L. Cox regression models were used to study the association between hsCRP and the study outcomes. Results: Compared to patients with hsCRP <2 mg/L ( n = 89, 38%), those with hsCRP >= 2 mg/L ( n = 143, 62%) had more frequent HF hospitalizations prior to randomization, chronic obstructive pulmonary disease, orthopnea, higher body mass index, and worse health -related quality -of -life. A hsCRP level >= 2 mg/L was associated with an increased risk of cardiovascular death and HF hospitalizations: hsCRP >= 2 mg/L vs <2 mg/L adjusted HR 2.36, 95%CI 1.27 - 4.38, P = 0.006. Spironolactone did not influence hsCRP levels from baseline to month 12: gMean ratio = 1.11, 95%CI 0.87 - 1.42, P = 0.39. Conclusions: A hsCRP >= 2 mg/L identified HFpEF patients with a high risk of HF events and cardiovascular mortality. Spironolactone did not influence hsCRP levels at 12 months.
Dados da publicação
- ISSN/ISSNe:
- 1874-1754, 0167-5273
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
International Journal of Cardiology Elsevier Ireland Ltd
Citações Recebidas na Web of Science: 7
Citações Recebidas na Scopus: 7
Documentos
- Não há documentos
Filiações
Keywords
- Heart failure with preserved ejection fraction; High-sensitivity C-reactive protein; Inflammation; Prognosis
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Initiation of ARNi and SGLT2i in Patients With HFrEF: Randomized Open-label Trial (INITIATE-HFrEF) -NCT05989503
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (INITIATE-HFrEF) . Novartis . 2023
Citar a publicação
Ferreira JP,Claggett BL,Liu JK,Sharma A,Desai AS,Anand IS,O'Meara E,Rouleau JL,De Denus S,Pitt B,Pfeffer MA,Zannad F,Solomon SD. High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT. Int. J. Cardiol. 2024. 402. 131818. IF:3,500. (2).
